VCG
TXG icon

Vantage Consulting Group’s 10x Genomics TXG Stock Holding History

Vantage Consulting Group’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7
Closed -$1K – 1473
2020
Q4 		$1K Buy
+7
New +$1.02K ﹤0.01% 1811

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
MCAV
Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vantage Consulting Group's TXG Position: Q1 2021 in Review

Vantage Consulting Group sold out of 10x Genomics (TXG) in Q1 2021, closing a stake of 7 shares — an estimated $1K sold.

Vantage Consulting Group first reported a position in TXG in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 324 funds tracked by Wall St. Rank hold TXG as of Q1 2021.

  • Vantage Consulting Group reported no remaining 10x Genomics position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 7 10x Genomics shares in Q1 2021, an estimated $1K.
  • Vantage Consulting Group first reported a position in 10x Genomics in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's 10x Genomics position peaked at $1K in Q4 2020.
  • 324 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.